ArticleNPJ cardiovascular health2025
The senescence-inducing factor IGFBP7 and risk of atrial fibrillation: findings from the PREVEND study.
Article in NPJ cardiovascular health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- IGFBP7 and Heart Failure: From Senescence Biomarker to Therapeutic Target.Current heart failure reports · 2026Review
- Bone morphogenetic protein 10: clinical correlates and risk of incident atrial fibrillation.American journal of physiology. Heart and circulatory physiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Experimental evidence supports the role of cellular senescence in the pathophysiology of atrial fibrillation (AF) and suggests that Insulin-like Growth Factor Binding Protein-7 (IGFBP7) is an important senescence-inducing factor. Whether elevated IGFBP7 levels precede the development of AF remains unknown. We measured IGFBP7 levels in plasma of 5884 adult participants without prevalent AF (mean age 53.6 ± 12.1 years; 51.5% women) from the PREVEND community-based cohort (2001-2004). Incident AF was ascertained from hospital and study electrocardiograms. During a median follow-up of 6.4 (5.9-6.9) years, 154 participants (2.6%) developed AF. In Cox proportional hazards models, IGFBP7 was associated with increased risk for incident AF (unadjusted hazard ratio [HR]: 1.85 per 1-SD increase in log-IGFBP7; 95% confidence interval [CI]: 1.65-2.07) which remained significant after adjustment for clinical variables (HR: 1.28; 95% CI: 1.07-1.52). Based on these data, we conclude that IGFBP7, a senescence-inducing factor, is associated with the risk of developing AF in community-dwelling adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.